CTOs on the Move

Aligos Therapeutics

www.aligos.com

 
Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aligos.com
  • 1 Corporate Dr
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Aligos Therapeutics raised $125M on 01/10/2020
Aligos Therapeutics raised $83.6M on 07/01/2021

Similar Companies

Cedilla Therapeutics

We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.

Geltor

Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.

Pain Therapeutics

Pain Therapeutics, Inc. is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MiMedx

MiMedx is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts. MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Adarza BioSystems Inc

Adarza BioSystems, Inc. manufactures a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.